Narayana Hrudayalaya Limited Approves Unaudited Q2 FY27 Results

Narayana Hrudayalaya Limited approved its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The Board took the decision on October 30, 2026, alongside the limited review report, following Q1 FY27 revenue of ₹2,683.63 crore, which was reported as 78.05% higher year on year.

What did Narayana Hrudayalaya approve at its October 30 meeting?

Narayana Hrudayalaya approved the unaudited financial statements for Q2 FY27 and the first half of FY27 at its Board meeting held on October 30, 2026. The approved set includes both standalone and consolidated results for the periods ended September 30, 2026.

The Board also approved the accompanying limited review report. The company said the Audit Committee considered the financial information and the statutory auditors reviewed the statements as part of the limited-review process. The results and reports have been submitted in line with applicable regulatory requirements.

The announcement confirms completion of the company’s scheduled second-quarter earnings process. Narayana Hrudayalaya had informed the market on October 26 that its Board would meet on October 30 to consider the unaudited standalone and consolidated results.

No detailed Q2 FY27 revenue, profit, margin, or earnings-per-share figures were included in the supplied announcement. As a result, the approval should be distinguished from the release of a detailed financial-results statement containing the period’s operating and financial metrics.

Which financial periods are covered by the approved results?

The approved statements cover the three months ended September 30, 2026, as well as the six months from April 1 to September 30, 2026. These periods represent the second quarter and first half, respectively, of FY27.

Standalone statements show the financial performance of the Indian listed entity, while consolidated statements include the financial performance of its subsidiaries and other entities within the group. Narayana Hrudayalaya operates a healthcare network across India and also has a presence in the Cayman Islands and the UK.

The company operates 55 healthcare facilities across India, according to the provided information. The consolidated format is therefore relevant for investors assessing performance across the wider group, while the standalone presentation provides the results of the parent company separately.

The limited review is not the same as a full-year audit. It is the review process generally applied to interim financial statements, with auditors examining the quarterly and half-year information before it is placed before the Board and submitted to the exchanges.

What was Narayana Hrudayalaya's financial position before Q2 FY27?

Narayana Hrudayalaya entered the September quarter after reporting higher revenue in Q1 FY27, ended June 30, 2026. Revenue was stated at ₹2,683.63 crore, compared with ₹2,593.81 crore in the preceding quarter, representing a 3.46% sequential increase.

The Q1 FY27 summary also showed that operating profit, profit before tax, and net profit were lower sequentially despite the reported growth in revenue. Net profit was ₹207.27 crore, down from ₹223.99 crore in the previous quarter, while still 5.37% higher than the comparable year-earlier period.

Separately, the company reported that Q1 FY27 EBITDA rose 40% year on year to ₹505.20 crore from ₹360.70 crore. It attributed the domestic hospital performance to high-end procedures, robotics and higher patient footfalls through its clinic model. The supplied information also said the India business net margin expanded by 400 basis points year on year.

What operating trends were reported ahead of the September quarter?

Narayana Hrudayalaya reported growth in its domestic hospital operations before the September-quarter results process. India hospital revenue increased 16.6% year on year to ₹1,319.60 crore in the reported period, while clinic outpatient consultations grew by about 30% year on year to 66,000 in Q1 FY27.

The company linked domestic EBITDA growth to higher-value procedures, the use of robotics and a clinic-led patient referral model. These indicators matter because hospital operators depend on occupancy, treatment mix, procedure volumes and operating costs to convert revenue growth into profitability.

Narayana Hrudayalaya had also said that 100 beds at Southwest Bangalore were expected to become operational by the end of Q2 FY27. The supplied announcement does not confirm whether the beds commenced operations by September 30, and the approved results notice does not provide a fresh capacity update.

For investors, the Q2 and half-year statements are relevant because they can show whether the reported growth in consultations and specialised procedures translated into revenue and operating performance during the September quarter. However, the provided Board-meeting disclosure does not provide the underlying Q2 figures needed to make that assessment.

How does the results approval affect investors and the hospital sector?

The Board approval confirms that Narayana Hrudayalaya has completed the governance and review steps for its September-quarter and first-half financial reporting. It provides a formal basis for the company’s regulatory filing of unaudited interim results.

The notice does not disclose a share-price movement, a market reaction, or updated earnings guidance. It also does not specify any changes in dividend policy, capital allocation, hospital expansion plans or management outlook. Any conclusion on market impact would therefore require the detailed financial statements and investor disclosures.

For the hospital sector, the reported Q1 trends highlight the importance of procedure mix, outpatient networks and efficient use of existing capacity. Narayana Hrudayalaya’s reported 40% year-on-year EBITDA growth in Q1 FY27 and planned additional Bangalore capacity provide context for the September-quarter disclosure, but do not establish the Q2 outcome on their own.

Conclusion

Narayana Hrudayalaya has approved its unaudited standalone and consolidated Q2 FY27 and first-half FY27 financial statements, together with the limited review report. The decision completes an important interim reporting step for a healthcare provider that had reported revenue growth and higher domestic operating performance in Q1 FY27.

The next point to watch is the detailed September-quarter filing, particularly its reported revenue, profitability, margins, clinic activity and any update on the planned 100-bed Southwest Bangalore expansion. The information supplied for the Board meeting confirms the approval but does not disclose these Q2 financial or operational outcomes.